P025: CRISPR/Cas9 nickase‐mediated inactivation of hepatitis B virus replication

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2893|22|S2|31-31

ISSN： 1352-0504

Source： JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol.22, Iss.S2, 2015-06, pp. : 31-31

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting Cdk11 in osteosarcoma cells using the CRISPR‐cas9 system

By  

JOURNAL OF ORTHOPAEDIC RESEARCH, Vol. 33, Iss. 2, 2015-02 ,pp. : 199-207

John Wiley & Sons Inc

Access to resources Recommend Favorite

CRISPR-Cas9, cellules germinales et embryon humain

By Jouannet Pierre  

Biologie Aujourd'hui, Vol. 211, Iss. 3, 2018-02 ,pp. : 207-213

Edp Sciences

Access to resources Recommend Favorite

CRISPR-Cas9, une nouvelle donne pour la thérapie génique

By Jordan Bertrand  

Médecine/sciences, Vol. 31, Iss. 11, 2015-11 ,pp. : 1035-1038

Edp Sciences

Access to resources Recommend Favorite

P022: The hepatitis B virus (HBV) surface antigen (HBsAg) prevents hepadnaviral replication‐dependent interferon responses, which are mediated by non‐parenchymal liver cells in a HBV transgenic mouse model

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 29-30

John Wiley & Sons Inc

Access to resources Recommend Favorite

Revolutionizing male fertility factor research in mice by using the genome editing tool CRISPR/Cas9

By  

Reproductive Medicine and Biology, Vol. 17, Iss. 1, 2018-01 ,pp. : 3-10

John Wiley & Sons Inc

Access to resources Recommend Favorite